Featured

Dimming IFN signaling to brighten CAR-T persistence and efficacy

While CAR T cell therapy has shown great success in hematological cancers, relapses may occur, and the therapy has so far shown limited efficacy in solid tumors. Based on their previous data, which showed that genetic deletion of IFNγ in CD19 CAR T...

An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses

Focused on improving long-term and cross-variant protective memory for mRNA vaccines, Aunins and Phan et al. first found that endogenous IL-12 was dispensable for generating CD8+ T cell responses to l...

CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

Stahl, Gödel, and Balke-Want et al. performed multimodal analysis of pre- and post-CAR T cell-treated tissue from patients with relapsed or refractory aggressive B cell lymphoma (B-NHL) and identified...

Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors

Yang et al. found that methotrexate (MTX) competitively inhibited the membrane cGAMP hydrolase ENPP1, which both enhanced immune cell activation by preventing loss of exogenous cGAMP, and inhibited do...

Secretion of a VEGF-blocking scFv enhances CAR T-cell potency

Analyzing scRNAseq data from CAR T cell infusion products, Supper and Donner et al. found that VEGFR1 was expressed in 41BB.z CAR T cells and associated negatively with treatment response. In vitro, a...

See all for this week

Previous Digests

A new off-the-shelf CAR T cell product made from iPSCs

June 11, 2025

CAR T cell therapies are well known for their potent capacity for killing antigen-expressing target cells. However, they are often hindered by factors in solid tumors and by challenges related to the development of an autologous T cell product...

Non-mutated tumor antigens in the spotlight for therapeutic targeting

June 4, 2025

Recent discoveries of unmutated aberrantly expressed tumor-specific antigens (aeTSAs) derived from non-coding regions and embryonic transcriptional programs has garnered attention as targets for immunotherapy. Apavaloaei et al. explored cell surface presentation of peptide:MHCs derived from mutated and unmutated tumor...

22nd CIMT Annual Meeting 2025

May 28, 2025

The ACIR team attended the 22nd CIMT Annual Meeting 2025 in Mainz, Germany. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. CIMT Lifetime achievement awardRolf Kiessling Keynote addressCornelis...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials